Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
諾華和瘧疾藥物風險投資公司公佈了CALINA2/3階段研究的數據，表明爲體重低於5Kg的瘧疾嬰兒開發的配方Coartem具有所需的藥代動力學特徵、良好的療效和安全性
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
諾華和瘧疾藥物風險投資公司公佈了CALINA2/3階段研究的數據，表明爲體重低於5Kg的瘧疾嬰兒開發的配方Coartem具有所需的藥代動力學特徵、良好的療效和安全性
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。